Diabetes mellitus and COVID-19: where Is the problem?

Marelys Yanes Quesada; Miguel Ángel Yanes Quesada; Jeddú Cruz Hernández; Raúl Orlando Calderín Bouza

2022, Number 3

<< Back

Rev Cuba Endoc 2022; 33 (3)

Diabetes mellitus and COVID-19: where Is the problem?

Yanes QM, Yanes QMÁ, Cruz HJ, Calderín BRO

Full text

How to cite this article

Language: Spanish
References: 31
Page:
PDF size: 513.19 Kb.

ABSTRACT

Introduction: COVID-19 is an acute respiratory disease caused by a virus of the coronavirus family called SARS-CoV-2, which can sometimes be serious. In people with diabetes mellitus, this entity may occur with a higher frequency and a worse prognosis.v Objective: To collect information about the possible influence of diabetes mellitus in the evolution of COVID-19. Methods: A search for information was performed in databases such as Google Scholar, PubMed, LILACS and SciELO, through the Google search engine.
Results: The main factors involved in the negative interaction between diabetes mellitus and COVID-19 are the alteration of the immune response present in people with diabetes and, consequently, the increase in susceptibility to acquiring infections, hyperglycemia, excessive inflammatory response and the presence of comorbidities.
Conclusions: COVID-19 has a worse evolution in people with diabetes mellitus. It is a disease that has a high global prevalence and represents an important problem related to the pandemic.

REFERENCES

Wu F, Zhao S, Yu B., Chen Y, Wang W, Song Z. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265-9. DOI: https://doi.org/10.1038/s41586-020-2008-3.
Organización Panamericana de la Salud. La OMS caracteriza a COVID-19 como una pandemia. 2020 [acceso 12/10/2021]. Disponible en: https://www3.paho.org/hq/index.php?option=com_content&view=article&id=15756:who-characterizes-covid-19-as-a-pandemic&Itemid=1926&lang=es.
Moya J. Editorial. Bol OPS/OMS Cuba. 2020 [acceso 12/10/2021];24(2). Disponible en: https://iris.paho.org/bitstream/handle/10665.2/52514/v24n2.pdf.pdf?sequence=1&isAllowed=y.
Medina CE, Hernández E. La diabetes mellitus en el contexto de la COVID-19. Revdosdic. 2020 [acceso 12/10/2021];3(3):e81. Disponible en: file:///C:/Users/GRISEL~1/AppData/Local/Temp/81-271-5-PB.pdf.
González R, Acosta F, Oliva E, Rodríguez S, Cabeza I. Diabetes, hiperglucemia y evolución de pacientes con la COVID-19. Rev. Cubana Med. Milit. 2021 [acceso 12/10/2021];50(2): Disponible en: http://www.revmedmilitar.sld.cu/index.php/mil/article/view/960.
Li Y, Han X, Alwalid O. Baseline characteristics and risk factors for short-term outcomes in 132 COVID-19 patients with diabetes in Wuhan China: A retrospective study. Diabetes Res Clin Pract. 2020;166:108299. DOI: https://doi.org/10.1016/j.diabres.2020.108299.
Lima M, Carrera C, Madera M, Marin W, Contreras M. COVID-19 y diabetes mellitus: una relación bidireccional. Clin Investig Arterioscler. 2021;33(3):151-7. DOI: https://doi.org/10.1016/j.arteri.2020.10.001.
Samanda M, Hernández J. Conocimientos iniciales de la inmunidad durante la infección por SARS-CoV-2. Boletín Científico del CIMEQ. 2020 [acceso 12/10/2021];1(12):2-3. Disponible en: https://files.sld.cu/cimeq/files/2020/05/Bol-CCimeq-2020-1-12-pag-2-3.pdf.
Andersen KG, Rambaut A, Lipkin WI. The proximal origin of SARS-CoV-2. Nat Med. 2020 [acceso 12/10/2021];26:450-5. Disponible en: https://www.nature.com/articles/s41591-020-0820-9.pdf.
Del Carpio L, García S, Contreras ER, González O. Caracterización clínica y del hemograma de pacientes con neumonía por COVID-19 en Veracruz, México. Rev Hematol Méx. 2020;21(4):205-9. DOI: https://doi.org/10.24245/rev_hematol.v21i4.4488
De Almeida B, Dualib P, Zajdenverg L, Rodrigues J, Dias de Souza F, Rodacki M. Severity and mortality of COVID-19 in patients with diabetes, hypertension and cardiovascular disease: A meta-analysis. Diabetol Metab Syndr. 2020;12:75:20-4. DOI: https://doi.org/10.1186/s13098-020-00586-4.
Pranad K, Dissanayake H, Ranathunga I. Prevention and management of COVID 19 among patients with diabetes. Diabetología. 2020;3:1440-12. DOI: https://doi.org/10.1007/s00125-020-05164-x.
Rao S, Lau A, So H. Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of SARS-CoV-2: A Mendelian Randomization analysis. Diabetes Care. 2020;43(7):1416-26. DOI: https://doi.org/10.2337/dc20-0643.
Fernandez C, Rysa J, Almgren P, Nilsson J, Engstrom G, Orho M, et al. Plasma levels of the proprotein convertase furin and incidence of diabetes and 215 mortality. J Intern Med. 2018;284:377-87. DOI: https://doi.org/10.1111/joim.12783.
Aleman L, Guerrero J. Hiperglicemia por sepsis: del mecanismo a la clínica. Rev Méd Chile. 2018;146(4):502-10. DOI: http://dx.doi.org/10.4067/s0034-98872018000400502.
Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents. 2020;56(2):106054. DOI: https://doi.org/10.1016/j.ijantimicag.2020.106054.
Camacho L. Hiperglucemia como factor pronóstico de mortalidad en pacientes con SARS-CoV-2. Rev Soc Peruana Med Inter. 2020;33(4):151-4. DOI: https://doi.org/10.36393/spmi.v33i4.562.
Yang L, Han Y, Nilsson-Payant B, Gupta V, Wang P, Duan X, et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell. 2020;27(1):125-36. DOI: https://doi.org/10.1016/j.stem.2020.06.015.
Paolo G, Luca M, Boscari F, Fioretto P, Maran A, Busetto L, et al. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diab Res Clin Pract. 2020;168. DOI: https://doi.org/10.1016/j.diabres.2020.108374.
Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AF, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020 [acceso 12/10/2021];18:546-50. Disponible en: https://www.thelancet.com/pdfs/journals/landia/PIIS2213-8587(20)30152-2.pdf.
Aguilar FR, Suclupe DO, Vega JA. Sindemia por COVID-19 y diabetes mellitus tipo II: una peligrosa interacción. Rev Electrón Zoilo. 2021 [acceso 06/10/2021];46(3). Disponible en: file:///C:/Users/GRISEL~1/AppData/Local/Temp/2742-7623-3-PB.pdf.
Inca D, Zurita E, Idrovo P, Navas L, Tixi L, Rendon J. Impact of diabetes in the immune response against SARS-CoV-2. Diabetes Intern Endoc. 2020 [acceso 06/10/2021];XII(1). Disponible en: file:///C:/Users/GRISEL~1/AppData/Local/Temp/9%20Impacto%20de%20la%20diabetes.pdf.
Moreno J, Siqueiros T, Moreno V, González E, Leal I, Ras Q. COVID-19, diabetes y el sistema inmunológico. Nova Scientia. 2021;13. DOI: https://doi.org/10.21640/ns.v13ie.2751.
Geerlings SE, Hoepelman A. Immune dysfunction in patients with diabetes mellitus. FEMS Immunol Med Microbiol. 1999;26:259-65.
Abregú AV, Carrizo TR, Díaz E, Velarde MS, Fonio MC, Bazán MC. Inflamación subclínica en diabetes tipo 1 infanto-juvenil. Acta Bioquím Clín Latinoam. 2015;49(4):393-8.
Laviada H, Leal I, Rodriguez E, Bastarrachea R. Working hypothesis for glucose metabolism and SARS-CoV-2 replication: Interplay between the hexosamine pathway and interferon RF5 triggering hyperinflammation. Role of BCG vaccine? Frontiers Endocrinol. 2020;11:524. DOI: http://doi.org/10.3389/fendo.2020.00514.
Wang Q, Fang P, He R, Li M, Yu H, Zhou L, et al. GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5. Sci Advances. 2020;6(16):eaaz7086. DOI: http://doi.org/10.1126/sciadv.aaz7086.
Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. J Chem Inf Model. 2020;71(15):762-8. DOI: http://doi.org/10.1093/cid/ciaa248.
Lozada I, Núñez C. COVID-19: respuesta inmune y perspectivas terapéuticas. Rev Perú Med Exp Salud Pública. 2020 [acceso 12/10/2021];37(2):312-9. Disponible en: http://www.scielo.org.pe/pdf/rins/v37n2/1726-4642-rins-37-02-312.pdf.
Wu D, Yang XO. TH17 Responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020;53(3):368-70. DOI: http://doi.org/10.1016/j.jmii.2020.03.005.
Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020 [acceso 12/10/2021];27:1451-4. Disponible: https://www.nature.com/articles/s41418-020-0530-3.pdf.